Highest-materiality recent filing
CEO Daniel Reis-Faria received 500,000 options, CFO Dany Vaiman 250,000, Executive Chairman Michael Heinrich 500,000.
ZeroStack to issue shares for 142M Zero Gravity tokens, settles convertible note
Texas Blocker issued 9.1M shares in exchange for 142M 0G tokens valued at ~$107M (Token FMV $0.7549).
Flora Growth Corp. renamed to ZeroStack Corp.; ticker changes to ZSTK effective Jan 29, 2026
Name change effective January 29, 2026 after board and shareholder approval.
Flora Growth appoints Larry Zeifman as director and audit committee chair
Larry Zeifman appointed to board, filling vacancy from Harold Wolkin's passing on Aug 25, 2025.
Settlement requires Jan 6, 2026 payment of 96,162 Solana, $1.75M cash, 111,550 shares at $6.90/share.
Flora Growth settles with former CEO Clifford Starke for $895K cash and 13,000 RSAs
Former CEO Clifford Starke executed separation agreement effective Dec 19, 2025; receives $895K cash payment.
Shareholders approved name change to 'ZeroStack Corp.' and creation of a new class of preferred shares.
Flora Growth enters $25M equity purchase agreement with White Lion Capital, expandable to $50M
Up to $25M initial commitment, expandable to $50M at company's discretion over 24 months.
Flora Growth reports over $401M in funding for ZeroStack; $0G token launched
Over $401M secured via $0G tokens, convertible notes, cash raise of $13.66M, and $22.88M in SOL.
Flora Growth files ATM prospectus to sell up to $3.45M in common shares
New ATM agreement with Revere Securities allows sale of up to $3,450,000 of common shares.
Flora Growth raises ~$402M in placements, exits cannabis, pivots to digital asset treasury
CEO Clifford Starke and Executive Chairman Sammy Dorf resigned; replaced by Daniel Reis-Faria (CEO) and Michael Heinrich (Executive Chairman).
Flora Growth enters ATM equity sales agreement with Revere Securities
Company may sell common shares from time to time via Revere Securities as agent.
Flora Growth board loses independent director majority after passing of Harold Wolkin
Director Harold Wolkin passed away August 25, 2025; he served on audit, compensation, and nominating committees.
Flora Growth completes 1-for-39 reverse stock split effective August 3, 2025
Share consolidation at 1-for-39 ratio, approved by board on July 10, 2025.
Proposal 4 (grant of Stock Appreciation Rights to CEO, CFO, Executive Chairman) rejected with 7.5M against vs 1.3M for.
Flora Growth raises $1.1M via private placement; funds to buy crypto assets
Issued 3,133,011 common shares at $0.30 and 726,992 pre-funded warrants at $0.2999.
Flora Growth receives Nasdaq delisting notice for failing $1.00 minimum bid price
Nasdaq notified Flora Growth on Feb 25, 2025 of non-compliance with $1.00 minimum bid price over 30 consecutive business days.
Flora Growth acquires United Beverage for $2.85M notes and 4.99% stock; insiders included as sellers
Acquired 100% of United Beverage Distribution Inc., a cannabis-infused drink distributor, for $2,845,700 in 5-year 6% notes and 923,744 Flora shares (4.99% of outstanding).
Flora Growth grants 1.235M RSAs and 440K SARs to executives with immediate vesting
CEO Clifford Starke receives 900,000 RSAs vesting immediately on December 15, 2024.
Flora Growth raises ~$3.6M in registered direct offering of 2.85M shares at $1.25/share
Net proceeds of approximately $3.1M after deducting placement fees and estimated expenses.
Flora Growth sells 425,000 shares at $1.67, raising ~$710k in registered direct offering
Gross proceeds of approximately $709,750 from sale of 425,000 common shares at $1.67 per share.
Flora Growth terminates ATM Sales Agreement with Aegis Capital Corp.
Mutual termination of ATM Sales Agreement with Aegis Capital Corp. effective December 12, 2024.
Flora Growth appoints Sammy Dorf as Executive Chairman, adds independent director
Director Brendan Cahill resigned on Dec 5, 2024; no disagreement with company.
Flora Growth enters new medicinal cannabis supply deal with Curaleaf affiliate for German market
Minimum purchase of 50 kg cannabis flos per year; Northern Green minimum supply 25 kg.
Flora Growth awards CEO Starke 575K, CFO Vaiman 192K stock appreciation rights at $0.9149 base price
Shareholders approved SARs for CEO Clifford Starke (575,319 rights) and CFO Dany Vaiman (191,773) at August 14, 2024 annual meeting.
Flora Growth appoints Harold Wolkin to regain Nasdaq audit committee compliance
Director Kevin Taylor resigned Aug 26, 2024; audit committee fell below three independent members, violating Nasdaq Rule 5605(c)(2)(A).
Flora Growth shareholders approve all proposals at 2024 annual meeting
All four directors elected: Starke, Taylor, Woo, Cahill each received >4.8M for votes.
Flora Growth acquires Australian Vaporizers for 550k shares valued at $0.7M
Acquired 100% of Australian Vaporizers Pty Ltd., an online vaporizer and accessories retailer in Australia.
Flora Growth acquires TruHC Pharma; TruHC audit shows going concern, minimal cash
TruHC Pharma GmbH acquired; first closing completed April 23, 2024.
Flora Growth regains Nasdaq compliance with appointment of independent director Brendan Cahill
Appointed Brendan Cahill as independent director effective May 2, 2024.
Flora Growth appoints Brendan Cahill as independent director to regain Nasdaq compliance
Brendan Cahill appointed independent director effective May 2, 2024; will serve on audit, compensation, and nominating committees.
Flora Growth enters into at-the-market equity offering agreement with Aegis Capital
ATM sales agreement with Aegis Capital Corp. allows Flora to sell common shares at its option.
Flora Growth completes first closing of TruHC Pharma acquisition; issues 2.14M shares worth ~$4.9M
First closing of TruHC Pharma GmbH acquisition; issued 2,135,199 common shares.
Flora Growth to acquire TruHC Pharma GmbH for $6.4M in shares in two closings
Acquires all shares of TruHC Pharma GmbH for 2,770,562 common shares valued at $6.4M based on $2.31/share.
Flora Growth announces $3.23M public offering of 1.7M shares at $1.90 each
Underwriting agreement with Aegis Capital Corp. for 1,700,000 common shares at $1.90/share.
Flora Growth to acquire TruHC Pharma GmbH for $6.4M in stock
Purchase price of US$6,400,000 payable in 2,770,562 FLGC common shares.
On August 29, 2024, the Board appointed Mr. Harold Wolkin as an independent director and member of each of the Company's audit committee, compensation committee and nominating and corporate governance committee.
On August 26, 2024, Mr. Kevin Taylor resigned as a director of the Company.
On May 2, 2024, the Board of Directors (the " Board ") of Flora Growth Corp. (the " Company ") appointed Mr. Brendan Cahill as an independent director and member of each of the Company's audit committee, compensation committee and nominating and corporate governance committee.
Max materiality 0.95 · Median 0.60 · Most common event other_material